PRDM9 and breast carcinoma: Furthermore, currently, there are no histone methyltransferases in clinical trials for the treatment of breast cancer, further highlighting the need for further investigation for histone methyltransferase-associated breast cancers, as well as the development of therapeutics targeting these enzymes.